Alefacept is well tolerated in patients with chronic plaque psoriasis.
Traditional systemic treatments for moderate to severe chronic plaque psoriasis are often poorly tolerated and are associated with safety concerns that restrict their long-term use. Alefacept is a fully human fusion protein that selectively targets memory T cells, and it is expected to provide enhanced safety over traditional nonselective agents. The safety and tolerability profile of alefacept is reviewed using data from the clinical development program. The most common adverse events were similar among alefacept and placebo groups. As expected from its mechanism of action, alefacept reduced the number of CD4(+) and CD8(+) T cells, with selectivity for the memory subsets. This reduction was not associated with an increase in the incidence of infections. Alefacept was not immunogenic. Patients have received up to 6 courses of alefacept therapy and the safety and tolerability profile over multiple courses is similar to that of a single course. Alefacept offers hope for a safer means to provide long-term management of psoriasis.
Gottlieb
Alice B
AB
Clinical Research Center, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA. gottliab@umdnj.edu
D000077944:Alefacept; D002908:Chronic Disease; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
D011993:Recombinant Fusion Proteins; D000077944:Alefacept